RU2020113234A - ПРИМЕНЕНИЕ АНТИТЕЛ, СВЯЗЫВАЮЩИХ IL-1β, ДЛЯ ЛЕЧЕНИЯ АЛКОГОЛЬНОГО ГЕПАТИТА - Google Patents

ПРИМЕНЕНИЕ АНТИТЕЛ, СВЯЗЫВАЮЩИХ IL-1β, ДЛЯ ЛЕЧЕНИЯ АЛКОГОЛЬНОГО ГЕПАТИТА Download PDF

Info

Publication number
RU2020113234A
RU2020113234A RU2020113234A RU2020113234A RU2020113234A RU 2020113234 A RU2020113234 A RU 2020113234A RU 2020113234 A RU2020113234 A RU 2020113234A RU 2020113234 A RU2020113234 A RU 2020113234A RU 2020113234 A RU2020113234 A RU 2020113234A
Authority
RU
Russia
Prior art keywords
subject
administration
canakinumab
gevokizumab
weeks
Prior art date
Application number
RU2020113234A
Other languages
English (en)
Russian (ru)
Other versions
RU2020113234A3 (enExample
Inventor
Шефард МПОФУ
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2020113234A publication Critical patent/RU2020113234A/ru
Publication of RU2020113234A3 publication Critical patent/RU2020113234A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
RU2020113234A 2017-09-13 2018-09-11 ПРИМЕНЕНИЕ АНТИТЕЛ, СВЯЗЫВАЮЩИХ IL-1β, ДЛЯ ЛЕЧЕНИЯ АЛКОГОЛЬНОГО ГЕПАТИТА RU2020113234A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762557929P 2017-09-13 2017-09-13
US62/557,929 2017-09-13
US201862647088P 2018-03-23 2018-03-23
US62/647,088 2018-03-23
PCT/IB2018/056928 WO2019053591A1 (en) 2017-09-13 2018-09-11 USE OF IL-1B BINDING ANTIBODIES FOR THE TREATMENT OF ALCOHOLIC HEPATITIS

Publications (2)

Publication Number Publication Date
RU2020113234A true RU2020113234A (ru) 2021-10-13
RU2020113234A3 RU2020113234A3 (enExample) 2022-04-28

Family

ID=63708416

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020113234A RU2020113234A (ru) 2017-09-13 2018-09-11 ПРИМЕНЕНИЕ АНТИТЕЛ, СВЯЗЫВАЮЩИХ IL-1β, ДЛЯ ЛЕЧЕНИЯ АЛКОГОЛЬНОГО ГЕПАТИТА

Country Status (14)

Country Link
US (3) US20200207848A1 (enExample)
EP (1) EP3717006A1 (enExample)
JP (1) JP2020533353A (enExample)
KR (1) KR20200052331A (enExample)
CN (1) CN111315412A (enExample)
AU (1) AU2018333106A1 (enExample)
BR (1) BR112020004903A2 (enExample)
CA (1) CA3075711A1 (enExample)
CL (1) CL2020000631A1 (enExample)
IL (1) IL273204A (enExample)
MX (1) MX2020002813A (enExample)
RU (1) RU2020113234A (enExample)
TW (1) TW201920269A (enExample)
WO (1) WO2019053591A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026145640A1 (zh) * 2025-01-03 2026-07-09 长春金赛药业有限责任公司 一种抗IL-1β抗体的药物组合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
ES2335232T3 (es) 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
AU2010306681A1 (en) * 2009-10-15 2012-04-19 Abbvie Inc. IL-1 binding proteins
US10000565B2 (en) * 2012-11-16 2018-06-19 Novartis Ag Use of IL-1 β binding antibodies for treating peripheral arterial disease
WO2015083120A1 (en) * 2013-12-04 2015-06-11 Novartis Ag USE OF IL-1β BINDING ANTIBODIES
MX2016014731A (es) * 2014-05-12 2017-05-04 Conatus Pharmaceuticals Inc Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa.
KR101695848B1 (ko) * 2015-03-03 2017-01-13 한국과학기술원 진세노사이드 f2를 포함하는 비알코올성 간 질환 또는 인슐린 저항성의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
TW201920269A (zh) 2019-06-01
WO2019053591A1 (en) 2019-03-21
JP2020533353A (ja) 2020-11-19
MX2020002813A (es) 2020-07-21
AU2018333106A1 (en) 2020-04-02
US20200207848A1 (en) 2020-07-02
CA3075711A1 (en) 2019-03-21
EP3717006A1 (en) 2020-10-07
IL273204A (en) 2020-04-30
US20230235043A1 (en) 2023-07-27
US20210309736A1 (en) 2021-10-07
RU2020113234A3 (enExample) 2022-04-28
CN111315412A (zh) 2020-06-19
CL2020000631A1 (es) 2020-09-11
KR20200052331A (ko) 2020-05-14
BR112020004903A2 (pt) 2020-09-15

Similar Documents

Publication Publication Date Title
US10471142B2 (en) Combination therapy using immunoglobulin and C1-Inhibitor
CN105380941A (zh) 苯酞类化合物药物用途及其医药组合物
KR20240032789A (ko) 시클로-히스프로를 유효성분으로 포함하는 비만 예방 또는 치료용 약제학적 조성물
CN109172550B (zh) 一种复合麻醉药物
CN109223870A (zh) 一种治疗头痛的喷雾剂
CN104825402B (zh) 一种含有吉西他滨的注射用药物组合物
JP2011111405A (ja) グリア細胞の活性化抑制組成物
CN106924588A (zh) 助眠降血压药酒
RU2412701C2 (ru) Способ снижения непереносимости противотуберкулезных препаратов
JP5823695B2 (ja) 肝機能障害予防剤
RU2633484C2 (ru) Новое применение мелатонина
RU2113241C1 (ru) Способ лечения алкоголизма "тройная защита"
WO2019226349A1 (en) Oral composition of citrus pectin and papain to decrease plasma free igf-1 levels in individuals who need it and methods of preparation in soft capsule and syrup dosage forms
CN112076310A (zh) 一种治疗多发性硬化的药物组合物及其制备
CN106912649A (zh) 具有降血压作用的保健茶
CN102552481A (zh) 一种通络降压中药组合物及其制备方法
CN106913787A (zh) 能够滋补肝肾的降血压保健茶
KR100835607B1 (ko) 감마-폴리글루탐산을 유효성분으로 함유하는 해수 질환의완화 및 치료제용 약학적 조성물
JP2020533353A5 (enExample)
CN1331482C (zh) 一种治疗乙肝、肝硬化的中药
TWI701035B (zh) 茯苓萃取物及土莫酸於保護肌肉之用途
CN106913789A (zh) 降血压绿萝花茶
CA2848510C (en) Combination therapy using immunoglobulin and c1-inhibitor
Injectable Oral t Second Generation Antihistamines see Drugs for the Management of Allergy, Cough, and Cold Symptoms pages 603 Topical Corticosteroids see page 574 Parenteral Corticosteroids see page 577 Oral Corticosteroids see page 577
CN103720748A (zh) 鸡血藤对Hepcidin的调控及其应用